HC Wainwright Lifts Earnings Estimates for MiNK Therapeutics

MiNK Therapeutics, Inc. (NASDAQ:INKT) – Investment analysts at HC Wainwright increased their FY2028 earnings estimates for MiNK Therapeutics in a research note issued to investors on Thursday, November 14th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of $0.24 per share for the year, up from their prior forecast of $0.16. HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($0.33) per share.

Separately, Robert W. Baird reduced their price objective on shares of MiNK Therapeutics from $8.00 to $4.00 and set an “outperform” rating for the company in a research report on Friday.

MiNK Therapeutics Price Performance

INKT stock opened at $0.75 on Monday. The company has a fifty day moving average price of $0.73 and a two-hundred day moving average price of $0.85. MiNK Therapeutics has a one year low of $0.57 and a one year high of $1.90. The stock has a market cap of $29.81 million, a price-to-earnings ratio of -1.93 and a beta of 0.05.

Institutional Investors Weigh In On MiNK Therapeutics

A hedge fund recently raised its stake in MiNK Therapeutics stock. Renaissance Technologies LLC lifted its position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 127,841 shares of the company’s stock after buying an additional 22,613 shares during the quarter. Renaissance Technologies LLC owned about 0.37% of MiNK Therapeutics worth $121,000 as of its most recent SEC filing. 2.87% of the stock is currently owned by institutional investors and hedge funds.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.